Vera Therapeutics Financial Statements
NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
29.88+0.15 (+0.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vera Therapeutics revenue and earnings
Vera Therapeutics reported a net loss of $299.6 million, compared with a loss of $152.1 million a year earlier. Diluted earnings per share came in at -$4.66.
Summary generated from market data by MetaCap's automated system. Methodology
Vera Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 315.47M | 167.17M | 102.01M | 90.90M | 34.40M | 52.24M |
| Research & Development | 215.26M | 126.17M | 78.22M | 68.99M | 22.48M | 45.21M |
| Operating Income | -315.47M | -167.17M | -102.01M | -90.90M | -34.40M | -52.24M |
| Interest Expense | 7.53M | 7.63M | 3.79M | 992.00K | 20.00K | 166.00K |
| Other Income (Expense) | 15.86M | 15.02M | 6.02M | 1.85M | 1.79M | -1.17M |
| Pretax Income | -299.61M | -152.15M | -95.99M | -89.06M | -32.61M | -53.41M |
| Income Tax | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | -1.00K |
| Net Income | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M | -53.41M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -166.93 |
| EPS (Diluted) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -166.93 |
| Shares Outstanding (Basic) | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M | 319.96K |
| Shares Outstanding (Diluted) | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M | 319.96K |
| EBITDA | -315.00M | -167.06M | -101.99M | -91.75M | -34.23M | -51.99M |
This table shows 6 annual periods of Vera Therapeutics's income statement, from FY 2025 back to FY 2020, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow VERA's reporting calendar. What is a income statement?